A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1

International Journal of Impotence Research

Volumn 17, Issue 4, 2005, Pages 346-353

  Seyam, R ^a   Mohamed, K ^b   Al Akhras, A ^b   Rashwan, H ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Drug therapy; Papaverine; Penile erection; Phentolamine; Prostaglandin E 1

Indexed keywords

PAPAVERINE; PHENTOLAMINE MESYLATE; PROSTAGLANDIN E1; VASORIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ECHOGRAPHY; ERECTILE DYSFUNCTION; HEMODYNAMICS; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PENIS ERECTION; PRIAPISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ALPROSTADIL; DRUG THERAPY, COMBINATION; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PAPAVERINE; PATIENT SATISFACTION; PHENTOLAMINE; PRIAPISM; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; VASODILATOR AGENTS;

EID: 22644445733     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901313     Document Type: Article

References (21)

1. Shabsigh R et al. Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). Urology 2000; 55: 477-480.
2. Hatzichristou DG et al. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197-1200.
3. Montague DK et al. Clinical guidelines panel on erectile dysfunction: summary report on the treatment of organic erectile dysfunction. The American Urological Association. J Urol 1996; 156: 2007-2011.
4. von Heyden B et al. A prostaglandin E1 dose-response study in man. J Urol 1993; 150: 1825-1828.
5. Ismail M, Abbott L, Hirsch IH. Experience with intracavernous PGE-1 in the treatment of erectile dysfunction: dose considerations and efficacy. Int J Impot Res 1997; 9: 39-42.
6. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 1564-1565.
7. Govier FE et al. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993; 150: 1822-1824.
8. Marshall GA, Breza J, Lue TF. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994; 43: 844-848.
9. Shenfeld O et al. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study. J Urol 1995; 154: 1017-1019.
10. Mulhall JP et al. The causes of patient dropout from penile self-injection therapy for impotence. J Urol 1999; 162: 1291-1294.
11. Montorsi F et al. Current status of local penile therapy. Int J Impot Res 2002; 14(Suppl 1): S70-S81.
12. Israilov S et al. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. Int J Impot Res 2002; 14: 38-43.
13. Rosen RC et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11: 319-326.
14. Kunelius P, Lukkarinen O. Intracavernous self-injection of prostaglandin E1 in the treatment of erectile dysfunction. Int J Impot Res 1999; 11: 21-24.
15. Hatzichristou D et al. Diagnostic steps in the evaluation of patients with erectile dysfunction. J Urol 2002; 168: 615-620.
16. Bechara A et al. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses. J Urol 1996; 155: 913-914.
17. Goldstein I et al. Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction. Alprostadil Alfadex Study Group. Int J Impot Res 2000; 12: 205-211.
18. Vanderschueren D et al. A study in patients with erectile dysfunction comparing different formulations of prostaglandin E1. Alprostadil Study Group. J Urol 1995; 154: 1744-1747.
19. Quam JP et al. Duplex and color Doppler sonographic evaluation of vasculogenic impotence. Am J Roentgenol 1989; 153: 1141-1147.
20. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996; 155: 802-815.
21. Casabe A et al. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction. Int J Impot Res 1998; 10: 5-9.